New multi-million kronor agreement for Sprint Bioscience
Sprint Bioscience and LG Chem have signed a cooperation and licensing agreement for research, development and commercialization of drug candidates. “We’re delighted about the agreement with LG Chem, an ideal partner to further develop this programme,” says Dr Anders Åberg, Sprint Bioscience CEO.
– We are very pleased to have signed the agreement with LG Chem, a perfect partner to further develop this program. The agreement also confirms the quality of our drug research programs and the global scope of our network in the pharmaceutical industry, “says Dr. Anders Åberg, CEO of Sprint Bioscience.
The agreement applies to Sprint Bioscience’s early development program for NASH and metabolic diseases and gives the company approximately USD 2.5 million for the first 12 months. Sprint Bioscience is entitled to approximately $ 230 million in potential preclinical, clinical and net sales-based interim payments. In addition, Sprint Bioscience is entitled to receive royalties on worldwide net sales of any resulting products from the collaboration.
– We enter into this collaboration with Sprint Bioscience to expand our portfolio in NASH and other metabolic diseases, says dr. Jeewoong Son, CEO of LG Chem Life Sciences Company.
NASH (Non-Alcoholic Steatohepatitis) is a serious liver disease where there is currently no treatment. Sprint Bioscience is working on a new mechanism of action and a new target protein involved in fat storage in the liver and other tissues, inflammatory response and fibrosis in NASH. Something that provides the opportunity to develop treatments that can slow the development of both early and late stages of NAFLD (Non-Alcoholic Fatty Liver Disease) / NASH.
Test your business idea: Flemingsberg Science Award Startup open for applications
STARTUP is a competition for startups with a clear connection to Flemingsberg, either as students, residents or otherwise active in the area.All ideas are welcome to participate in STARTUP as long as you compete with your own idea and the turnover and external equity is below SEK 1,000,000 at the time you submit to the competition. After that, we of course welcome you to continue working with the business idea, sales and any investments.
SMI invites you to a Christmas lunch concert
Stockholm Music Education Institute, SMI invites you to a Christmas percussion concert on December 12. Percussion students and teachers perform a varied program and a porridge lunch with Christmas porridge, ham sandwich, lussebulle, gingerbread and coffee is served for only SEK 60. Lunch is served from 11.30 and the concert starts at 12.
Event: Welcome to our new coworking and meeting place at Campus Flemingsberg
Stockholm aims to become a world-leading life science cluster. To succeed, the city needs expertise, research facilities, cooperation and cross-border meeting places where creative collaborations can occur. Welcome to a launch event where we will shed light on what's needed to set us all on the right path.
DRIVE is looking for new startups – application deadline August 26
In the incubator DRIVE, you can build your Life Science startup in a unique environment. Now they are looking for new startups and the deadline for applications is August 26. DRIVE is KI Innovation's business incubator with a focus on life science and health.
How can the ATMP facilities at KI and Karolinska support your product development?
Developing Advanced Therapy Medicinal Products (ATMPs) is a growing field. Karolinska Institute and Karolinska University Hospital have unique facilities and expertise in this field.
“We want to increase the interest from the industry to collaborate with researchers”
The pre-GMP laboratory at Karolinska Institutet gives companies the opportunity to develop products, drugs and treatments. It is hoped for an increased interest from the industry to cooperate. Professor Matti Sällberg, head of the pre GMP unit, talks more about how this can be helpful early in the development.
